Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.72 |
| ▸ | PPARA | Q07869 | 15/20 | 0.72 |
| ▸ | PPARD | Q03181 | 9/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532479 | 0.95 | PPARG (0.64) | PPARGPPARAPPARDPTGS2P2RX4 | |
| SCHEMBL7853921 | 0.94 | PPARG (0.80) | PPARGPPARAPPARD | |
| SCHEMBL7531212 | 0.94 | PPARG (0.80) | PPARGPPARAPPARD | |
| SCHEMBL7527495 | 0.89 | PPARA (0.90) | PPARGPPARAPPARD | |
| SCHEMBL7533813 | 0.89 | PPARG (0.77) | PPARGPPARAPPARDPTGS2 | |
| SCHEMBL7528123 | 0.87 | PPARG (0.72) | PPARGPPARAPPARDPTGS2 | |
| SCHEMBL7527128 | 0.86 | PPARG (0.83) | PPARGPPARAPPARD | |
| SCHEMBL7533444 | 0.86 | PPARG (0.67) | PPARGPPARAPPARD | |
| SCHEMBL7845343 | 0.86 | PPARG (0.83) | PPARGPPARAPPARD | |
| SCHEMBL7535774 | 0.86 | PPARG (0.83) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6468996-B1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ACTIVATORS; TREATMENT OF DIABETES AND OBESITY. | NOVO NORDISK A/S (DK) | 2002-10-22 | — | — | US | claimed |
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | claimed |
| US-20020111344-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | JEPPESEN LONE (DK) | 2002-08-15 | — | — | US | claimed |
| US-6468996-B1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ACTIVATORS; TREATMENT OF DIABETES AND OBESITY. | NOVO NORDISK A/S (DK) | 2002-10-22 | — | — | US | disclosed |
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-20020111344-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | JEPPESEN LONE (DK) | 2002-08-15 | — | — | US | disclosed |
| US-20020103188-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | JEPPESEN LONE (DK) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103188-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20020111344-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.